Vital signs: lipid regulators were the third-best-selling drug class in 2010
J U L Y 2 0 1 1 • C A R D I O L O G Y N E W S HEART OF THE MATTER President, IMNG Alan J. Imhoff Editor in Chief Mary Jo M. Dales Executive Director, Operations Jim Chicca
placebo group, in order to reach a target
Director, Production/Manufacturing Yvonne Executive Editors Denise Fulton, Kathy Scarbeck
and Blood Institute announcedthat the Atherothrombosis In-
Managing Editor Catherine Hackett Production Manager Judi Sheffer
niacin plus statin was reported to be more
Senior Editors Christina Chase, Kathryn Production Specialists Maria Aquino, Anthony
effective than ezetimibe plus statin in re-
Keith Haglund, Gina L. Henderson, Sally Koch
Creative Director Louise A. Koenig Design Supervisor Elizabeth Byrne Lobdell
ing terminated because of the futility of
the ARBITER 6-HALTS study (N. Engl. J.
Jane Salodof MacNeil, Renée Matthews,Catherine Cooper Nellist, Amy Pfeiffer, Terry
Senior Designers Sarah L.G. Breeden, Yenling Liu
showing benefit, the study’s failure made
Designer Lisa M. Marfori Editorial Production Manager Carol Nicotera-Ward Photo Editor Catherine Harrell Web Production Engineer Jon Li Associate Editors Felicia Rosenblatt Black,
lation, and interested public ask “why?” at
until the full results of AIM-HIGH are re-
Therese Borden, Lorinda Bullock, Jay C. Web Production Specialist Jennifer Calhoun
ported before integrating the findings into
Cherniak, Richard Franki, Virginia Ingram-Wells, Jane Locastro, January W. Payne
their clinical practice, and that patients
Sales Director, IMNG Reporters Chicago: Patrice Wendling; Denver: National Account Manager
Philadelphia: Mitchel L. Zoler; San Diego:
Doug Brunk; San Francisco: Sherry Boschert,
Advertising Offices 60 Columbia Rd.,
Robert Finn; Washington: Alicia Ault, Frances
Correa, Elizabeth Mechcatie, Naseem S.
Miller, Heidi Splete, Miriam E. Tucker, Kerri
Classified Sales Manager, IMNG Multimedia Producer Nick Piegari Contributing Writers Christine Kilgore, Classified Sales Representative A N T O N I O M . Project Manager Susan D. Hite G O T T O J R . , M . D . Assignments Manager Megan Evans Reprints/Eprints Editorial Offices 5635 Fishers Lane, Suite
sufficiently powered. A clinical trial cur-
with the cholesteryl ester transfer protein
Sr. Program Manager, Customized Programs
cetrapib, so the final results are far from
Audience Development Manager Barbara Cavallaro, Address Changes Fax change of address (with
old mailing label) to 973-290-8245 or e-mail
Program/Marketing Manager Jennifer Eckert Business Controller Dennis Quirk Director of Information Technology Doug Adv. Services Manager Joan Friedman Credit Supervisor Patricia H. Ramsey Senior Systems Administrators Lee J. Unger,
raising HDL will be beneficial, and there
Manager, Administration/Conventions Lynne
aims to enroll 25,000 subjects, so this dif-
Systems Administrator/Application Support Receptionist Linda Wilson Accounts Payable Coordinator Daniela Silva
must indicate large differences in expect-
support for the “HDL hypothesis,” but
CARDIOLOGY NEWS is an independent newspaper
neither does it drive the final nail in the
that provides the practicing specialist with timely
old mailing label) to CARDIOLOGY NEWS Circula-
and relevant news and commentary about clinical
tion, 60 Columbia Rd., Bldg. B, 2nd flr., Morris-
decrease in events reported with niacin in
developments in the field and about the impact of
the Coronary Drug Project ( J. Am. Coll.
health care policy on the specialty and the
CARDIOLOGY NEWS (ISSN 1544-8800) is published
DR. GOTTO is the Stephen and Suzannemonthly by International Medical News Group,
background of placebo. Statins have set a
Weiss Dean and Professor of Medicine atLLC, an Elsevier company, 60 Columbia Rd., Bldg.
very high bar for efficacy, and it can be dif-
Weill Cornell Medical College, New York. HeB, 2nd flr., Morristown, NJ 07960, 973-290-8200, fax
EWS do not necessarily reflect those of the
Publisher. International Medical News Group,
973-290-8250. Subscription price is $114.00 per year.
ficult to demonstrate incremental benefit
is a consultant for AstraZeneca, KOWA, and
LLC, an Elsevier company, will not assume
Copyright 2011, by Elsevier Inc.
with an add-on to statin therapy, as was the
Merck; sits on the Board of Directors for
responsibility for damages, loss, or claims of any
Aegerion Pharmaceuticals and Arisaph
kind arising from or related to the information
ibe. In fact, there was substantial use of
Pharmaceuticals; and is a member of
contained in this publication, including any claimsrelated to the products, drugs, or services
INTERNATIONAL advisory boards for DuPont and VateraMEDICAL NEWS Lipid Regulators Were the Third–Best-Selling Drug Class in 2010 Oncologics
40% increase in the risk of bladder cancer.
Respiratory agents
crease the risk of bladder cancer, the Food
da), is also available in combination with
Lipid regulators Antidiabetes agents Antipsychotics
most 200,000 patients with type 2 diabetes
not be used in patients with active bladder
Antiulcerants
found that overall, there was no increased
cancer, and that it be used cautiously in pa-
Antidepressants
risk of bladder cancer pioglitazone users
tients with a history of bladder cancer. Autoimmune agents
ment for age, sex, smoking, use of other di-
HIV antivirals
abetes medications, and other risk factors.
authorities in June to suspend the use of
Angiotensin II receptor blockers
However, the risk did increase with higher
ties to proscribe starting pioglitazone treat-
Note: Figures represent U.S. wholesale revenue in billions.
Source: IMS Institute for Healthcare Informatics
–Elizabeth Mechcatie
Pharmacy Case Based Exam I Directions: Review the following Subjective and Objective findings and then, complete the SOAP note by writing an Assessment, Goals, and Plan. Also complete preparepharmacokinetic monitoring forms for each anticonvulsant. Make sure you accuratelycomplete these forms. Weighting of Items: Assessment , Goals, and Plan = 63 points; Monitoring Forms = 25 points
5 settembre 2006 USO DEL FARMACO FINASTERIDE In riferimento alle richieste di esenzione presentate per l’assunzione di finasteride nel trattamento dell’alopecia si riporta quanto recentemente indicato dal CEFT: “…il CEFT analogamente all’orientamento internazionale ed in particolare della WADA, non ritiene di concedere esenzione per assunzione di finasteride, in quanto non appaio